Picture loading failed.

Anti-CD3E;MS4A1 therapeutic antibody (Pre-made Epcoritamab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Envafolimab is a novel, single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-189-1mg 1mg Inquiry
GMP-Bios-ab-189-10mg 10mg Inquiry
GMP-Bios-ab-189-100mg 100mg Inquiry
GMP-Bios-ab-189-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-CD3E;MS4A1 therapeutic antibody (Pre-made Epcoritamab biosimilar,Bispecific mAb)
INN Name Epcoritamab
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda;Kappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;3giz:HL/6y92:BA:HL
Year Proposed2019
Year Recommended2020
Conditions Approvedna
Conditions ActiveHaematological malignancies;Diffuse large B-cell lymphoma;Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma
Conditions Discontinuedna
Development Techna